遗传预测的成纤维细胞生长因子-23与心力衰竭的关联:一项孟德尔随机化研究
采用两样本孟德尔随机化,以PIP5K1B、RGS14、LINC01229和CYP24A1附近的全基因组显著变异为工具,分析其与总体心力衰竭、射血分数保留的心力衰竭及射血分数降低和中段的心力衰竭的关联。在心力衰竭分子流行病学治疗靶点联盟中,遗传预测的FGF23与总体心力衰竭无关联(OR 1.13,95%CI 0.89-1.42);在BioVU全样本中亦无关联(OR 1.32,95%CI 0.95-1.84)。在BioVU低eGFR多基因风险评分(低于均值1个标准差)个体中,较高的FGF23与总体心力衰竭相关(OR 3.09,95%CI 1.38-6.91),与射血分数保留的心力衰竭相关(OR 7.20,95%CI 2.80-18.49),高评分组无关联(交互P分别为0.02和2.25×10⁻⁴)。
要点
- 在心力衰竭分子流行病学治疗靶点联盟中,遗传预测的FGF23与总体心力衰竭无关联(OR 1.13,95%CI 0.89-1.42)。
- 在BioVU全样本中,遗传预测的FGF23与总体心力衰竭无关联(OR 1.32,95%CI 0.95-1.84)。
- 在BioVU低eGFR多基因风险评分个体中,较高的FGF23与总体心力衰竭(OR 3.09,95%CI 1.38-6.91)和射血分数保留的心力衰竭(OR 7.20,95%CI 2.80-18.49)相关。
核心结论
- 在心力衰竭分子流行病学治疗靶点联盟中,遗传预测的FGF23与心力衰竭无关联。
- 在BioVU中,遗传升高的FGF23与较高的心力衰竭风险相关,特别是射血分数保留的心力衰竭,尤其在遗传预测的eGFR较低的个体中。
研究设计与样本
- 两样本孟德尔随机化研究,遗传工具为与FGF23相关的全基因组显著遗传变异,包括PIP5K1B、RGS14、LINC01229和CYP24A1附近的变异。
- 分析心力衰竭分子流行病学治疗靶点联盟和BioVU生物样本库的数据,检验四个变异与总体心力衰竭、射血分数保留的心力衰竭及射血分数降低和中段的心力衰竭的关联。
主要发现
- 在心力衰竭分子流行病学治疗靶点联盟中,遗传决定的FGF23与总体心力衰竭无关联(遗传预测的对数FGF23每升高一个单位,OR 1.13,95%CI 0.89-1.42)。
- 在BioVU全样本中,遗传决定的FGF23与总体心力衰竭无关联(遗传预测的对数FGF23每升高一个单位,OR 1.32,95%CI 0.95-1.84)。
- 在BioVU低eGFR多基因风险评分(低于均值1个标准差)个体中,较高的FGF23与总体心力衰竭相关(OR 3.09,95%CI 1.38-6.91),高评分组无关联(交互P=0.02)。
- 在BioVU所有参与者中,较高的FGF23与射血分数保留的心力衰竭相关(OR 1.47,95%CI 1.01-2.14);在低eGFR多基因风险评分个体中相关(OR 7.20,95%CI 2.80-18.49),高评分组无关联(交互P=2.25×10⁻⁴)。
- 未观察到与射血分数降低和中段的心力衰竭的显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Elevated fibroblast growth factor-23 (FGF23) has been consistently associated with heart failure, particularly heart failure with preserved ejection fraction, among patients with CKD and in the general population. FGF23 may directly induce cardiac remodeling and heart failure. However, biases affecting observational studies impede robust causal inferences. Mendelian randomization leverages genetic determinants of a risk factor to examine causality. We performed a two-sample Mendelian randomization to assess causal associations between FGF23 and heart failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Genetic instruments were genome-wide significant genetic variants associated with FGF23, including variants near PIP5K1B, RGS14, LINC01229, and CYP24A1. We analyzed data from the Heart Failure Molecular Epidemiology for Therapeutic Targets and BioVU biobanks to examine associations of the four variants with overall heart failure, heart failure with preserved ejection fraction, and heart failure with reduced and mid-range ejection fraction. We developed an eGFR polygenic risk score using summary statistics from the Chronic Kidney Disease Genetics Consortium (CKDGen) genome-wide association study of eGFR in >1 million individuals and performed stratified analyses across eGFR polygenic risk score strata. RESULTS: Genetically determined FGF23 was not associated with overall heart failure in the Heart Failure Molecular Epidemiology for Therapeutic Targets consortium (odds ratio, 1.13; 95% confidence interval, 0.89 to 1.42 per unit higher genetically predicted log FGF23) and the full BioVU sample (odds ratio, 1.32; 95% confidence interval, 0.95 to 1.84). In stratified analyses in BioVU, higher FGF23 was associated with overall heart failure (odds ratio, 3.09; 95% confidence interval, 1.38 to 6.91) among individuals with low eGFR-polygenic risk score (<1 SD below the mean), but not those with high eGFR-polygenic risk score (P interaction = 0.02). Higher FGF23 was also associated with heart failure with preserved ejection fraction among all BioVU participants (odds ratio, 1.47; 95% confidence interval, 1.01 to 2.14) and individuals with low eGFR-polygenic risk score (odds ratio, 7.20; 95% confidence interval, 2.80 to 18.49), but not those high eGFR-polygenic risk score (P interaction = 2.25 × 10-4). No significant associations were observed with heart failure with reduced and midrange ejection fraction. CONCLUSION: We found no association between genetically predicted FGF23 and heart failure in the Heart Failure Molecular Epidemiology for Therapeutic Targets consortium. In BioVU, genetically elevated FGF23 was associated with higher heart failure risk, specifically heart failure with preserved ejection fraction, particularly among individuals with low genetically predicted eGFR. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_07_28_CJN00960122.mp3.
引用
- Akwo E, Pike MM, Ertuglu LA, et al. Association of Genetically Predicted Fibroblast Growth Factor-23 with Heart Failure: A Mendelian Randomization Study. Clin J Am Soc Nephrol. 2022. PMID: 35902130. doi:10.2215/CJN.00960122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。